For the quarter ending 2026-03-31, DARE made $152,455 in revenue. -$2,955,347 in net income. Net profit margin of -1938.50%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 152,455 | - | - | - |
| Cost of revenues | 242,325 | - | - | - |
| Selling, general and administrative | 2,248,566 | - | - | - |
| Loss from operations | - | -1,713,729.5* | -3,672,148 | -3,827,800 |
| Sale of royalty and milestone rights, net | - | 0* | 0 | 0 |
| Interest expense | - | 100,153* | 213,171 | 268,533 |
| Research and development | 660,462 | - | - | - |
| Interest income | - | 96,247.5* | 319,147 | 69,848 |
| Total operating expenses | 2,909,028 | - | - | - |
| Other income (expense), net | - | 275,917* | 3,406 | 10,002 |
| Loss from operations | -2,998,898 | - | - | - |
| Net loss | -2,999,889 | -1,441,718 | -3,562,766 | -4,016,483 |
| Net loss to common stockholders | - | -1,431,743* | - | - |
| Foreign currency translation adjustments | 44,542 | -22,739* | 6,860 | - |
| Comprehensive loss | -2,955,347 | -1,454,482 | -3,555,906 | - |
| Basic EPS | -0.21 | -0.102 | -0.28 | -0.45 |
| Diluted EPS | -0.21 | -0.102 | -0.28 | -0.45 |
| Basic Average Shares | 14,522,835 | 14,329,688 | 12,755,112 | 8,871,155 |
| Diluted Average Shares | 14,522,835 | 14,329,688 | 12,755,112 | 8,871,155 |
Dare Bioscience, Inc. (DARE)
Dare Bioscience, Inc. (DARE)